2022 BIOPACIFIC CONFERENCE
Theme: Resilience and Ingenuity — Embracing Opportunities in a New Normal
| 8:00 AM – 8:50 AM REGISTRATION | |
| 8:50 AM -– 8:55 AM | Welcome Remarks (Virtual) Yuying (Kate) You, PhD, JD, President-elect of CABS and Chair of Organizing Committee of 2022 BioPacific Conference |
| 8:55 AM –- 9:00 AM | State of the Society Carrie Wang, MD, President of CABS |
| Morning Session 1 -Session Chair: Hesong Sun, PhD | |
| 9: 00 AM –- 9:35 AM | Keynote: Genentech’s Approach to Small Molecule Drug Discovery: Perspectives on Challenges and Opportunities Dan Sutherlin, PhD, SVP, Small Molecule Discovery Chemistry, Genentech |
| 9: 35 AM –- 10:05 AM | Cancer Fitness Genes: Emerging Therapeutics Targets for Metastatic Cancers Yibin Kang, PhD, Warner-Lambert/Parke-Davis Professor, Princeton University |
| 10:05 AM –- 10:15 AM | CABS K. Fong Award in Life Presenter: Kenneth Fong, PhD, Chairman, Kenson Ventures Awardee: Scott Liu, PhD, Founder and CEO, Hanchor Bio Inc. (Co-Founder and former CEO, Henlius) |
| 10:15 AM –- 10:35 AM | Navigating New Territory in Immuno-Oncology through the Development of Multi Functional Fc-Based Designer Biologics Scott Liu, PhD, Founder and CEO, Hanchor Bio Inc. (Co-Founder and former CEO, Henlius) |
| 10:35 AM-10:50 AM – 1st Coffee Break | |
| Morning Session 2 – Session Chair: Guanghui Han, PhD | |
| 10:50 AM –- 11:30 AM | Fireside Chat: The Birth and Growth of Turning Point Therapeutics — Founders’ Prospective Moderator: Kenneth Fong, PhD, Chairman, Kenson Ventures Speakers: Yishan (Peter) Li, PhD, MBA, Co-Founder, Executive Chairman, Blossom Hill Therapeutics, Inc.; Co-Founder, CEO and Chairman (10.2013-10.2018), Turning Point Therapeutics, Inc. J. Jean Cui, PhD, Co-Founder, President/CEO, Blossom Hill Therapeutics, Inc.; Co-Founder, CSO (10.2013-1.2020), Director, Turning Point Therapeutics, Inc.; Lead inventor of Crizotinib, Lorlatinib, Repotrectinib, Elzovantinib (TPX-0022), TPX-0046, TPX-0131. |
| 11:30 AM –- 12:10 PM | Panel Discussion: Healthcare Investment Trends and Strategies Moderator: Ella Mengyao Li, PhD, CEO, Hanhai Biolabs Panelists: Orrin Ailloni-Charas, MD, MBA, Founder and Managing Partner, Cura Capital Neil J. Littman, MSc, Founder, Bioverge Venture Cheni Kwok, PhD, CLP, Managing Partner & Founder, Linear Dreams |
| 12:10 PM — 1:15 PM-Lunch Break Noon Sessions: “Enabling Solutions for Drug Discovery: from Start to Approval” |
|
| Concurrent Session A (in Room Synergy 1). Chair: Yanan Wang, PhD | |
| 12:20 PM –- 12:35 PM | Leveraging Innovative Processes and Manufacturing to Accelerate the Quality Development of Advanced Cell and Gene Therapeutics YangZhou Wang, PhD, CEO, Porton Advanced Solutions |
| 12:35 PM –- 12:45 PM | End-to-end Drug Discovery Solutions Connie Sun, PhD, SVP, Global Head of BD, Small Molecules, Pharmaron |
| 12:45 PM –- 12:55 PM | Pharmaron Clinical – An Integrated Global Clinical Service Platform Charles Li, VP, Business Development, Pharmaron |
| 12:55 PM -– 01:10 PM | Selection of Raw Materials for Cell & Gene Therapy Tracy Zhao, Sr. Field Application Scientist, ACROBiosystems |
| Concurrent Session B (in Room Synergy 5). Chair: Vivian Liu, PhD | |
| 12:20 PM –- 12:30 PM | Next-Generation DMSO- & Serum-Free Cryopreservation for Cell Therapy Manufacturing and Processing Xiaoxi Wei, PhD, Co-Founder & CEO, X-Therma |
| 12:30 PM –- 12:40 PM | Accelerating Molecules to Market Min Park, MBA, Chief Business Officer, Aton Biotech – A Henlius Company |
| 12:40 PM –- 12:50 PM | Drug Safety: The Concept, Inception, and Its Importance Michael Zhao, Q Bay Boston Partner, Q Bay |
| 12:50 PM -– 01:00 PM | A New Era for Biotech Founders Jian Jiang, PhD & Linda Zhou, Partners, K&L Gates |
| 01:00 PM -– 01:10 PM | Biortus, from Gene to Lead: Your Partner in Drug Discovery lean Chai, Associate Director, Business Development, Biortus |
| Afternoon Session 1 – Session Chair: Zhiyong Yang, PhD | |
| 1:15 PM –- 1:50 PM | Keynote: Structural Biology in the Era of Single Particle Cryo- Yifan Cheng, PhD, Professor, HHMI Investigator, UCSF |
| 1:50 PM –- 2:10 PM | Keynote: A Day in the Life of a Medicinal Chemist – Discovery of Sotorasib Jennifer Allen, PhD, Executive Director of Medicinal Chemistry, Amgen |
| 2:10 PM –- 2:45 PM | Panel Discussion: Surviving the Valley of Death in Drug Discovery with the Right Mice in 2:45 PM a Good Incubator
Moderator: Yan Wang, PhD, Director, Peptide Chemistry, ChemPartner |
| 2:45 PM – 3:00 PM – 2nd Coffee Break | |
| Afternoon Session 2 – Session Chair: Xi Fang, PhD | |
| 3:00 PM –- 3:30 PM | Emerging Technology Program (Virtual) Anjali Shukla, PhD, Team Lead, Office of Biotechnology Products, FDA Center for Drug Evaluation and Research |
| 3:30 PM –- 4:00 PM | Partnerships to Build Resilience and Accelerate Innovation Amit Mehta, PhD, Vice President and the Head of Business Development, Genentech |
| 4:00 PM –- 4:35 PM | Panel Discussion: Al in Pharma and Life Sciences Moderator: Yang Shao, PhD, Director of Production Operations, Curia Bio Panelists: Michelle Chen, PhD, Chief Business Officer, Insilico Medicine Abraham Heifets, PhD, CEO, Atomwise Hogene Choi, JD, Partner, Morrison Foerster LLP |
| 4:35 PM –- 4:40 PM | Day Program Closing Remarks & Introduction of Night Program Jessica Sun, PhD, Vice Chair of Organizing Committee of 2022 BioPacific Conference |
| 4:40 PM – Day Program Adjourned | |
For very limited sponsorship opportunities, please contact: fundraising@cabsweb.org ASAP!
CABS
